AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

MedLife S.A.

Regulatory Filings Oct 9, 2025

2292_iss_2025-10-09_9ba30edf-e8ec-43eb-9f4b-f68de75d2fa7.pdf

Regulatory Filings

Open in Viewer

Opens in native device viewer

MED LIFE S.A.

Registered Office: Bucharest, 365, Calea Grivitei, 1st district, Romania Unique Registration Code at the National Office of Trade Registry: 8422035 Order number on the Trade Registry: J40/3709/1996 Subscribed and paid-in share capital: 132,870,492 RON

No. 81 / 9 October 2025

To: BUCHAREST STOCK EXCHANGE FINANCIAL SUPERVISORY AUTHORITY

CURRENT REPORT

Current report drafted according to the stipulations of ASF Regulation no. 5/2018 on issuers of financial instruments and market operations, Law no. 24/2017 on issuers of financial instruments and market operations (republished), and the provisions of Article 99 of the Bucharest Stock Exchange Code, Title II, Issuers and Financial Instruments

Report Date: 9 October 2025

Name of the issuing company: MED LIFE S.A. ("MedLife" or "the Company")

Registered Office: Bucharest, 365 Calea Grivitei, district 1, Romania

Telephone / Fax number: 0374 180 470

Unique Registration Code at the National Office of Trade Registry: 8422035

Order number on the Trade Registry: J1996003709402

EUID: ROONRC.J1996003709402

Subscribed and paid-in share capital: RON 132,870,492

Total number of shares: 531,481,968 (out of which 665,983 shares without voting rights and

530,815,985 shares with voting rights)

Regulated market on which the issued securities are traded: Bucharest Stock Exchange, Premium

Category

Significant events to report:

Closed trading period: 15 October – 13 November 2025

MED LIFE S.A. informs investors that between 15 October – 13 November 2025, the persons who have access to privileged information ("insiders") according to the provisions of FSA Regulation no. 5/2018, Law no. 24/2017 and EU Regulations no. 522/2016 and no. 596/2014 respectively, do not have the right to carry out any transactions in their own name or on behalf of a third party, directly or indirectly, related to shares, bonds, securities, debt or other derivative financial instruments of the Company.

This closed trading period occurs as a result of the fact that on 14 November 2025, the Company will publish the Q3 2025 Results Report.

Mihail Marcu

______________

Chief Executive Officer

Talk to a Data Expert

Have a question? We'll get back to you promptly.